Pasithea Therapeutics Secures $60 Million Funding to Advance MEK Inhibitor for Neurofibromatosis Treatment
核心洞察
Pasithea Therapeutics completed a $60 million public offering led by prominent healthcare investors to fund development of PAS-004, a next-generation MEK (搜索) inhibitor.
The company is currently testing PAS-004 in Phase 1 clinical trials for advanced cancer (搜索) patients and Phase 1/1b trials for neurofibromatosis type 1 (搜索)-associated plexiform neurofibromas (搜索).
The funding extends Pasithea's cash runway through at least the first half of 2028, supporting ongoing clinical development and research activities.
Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) announced the successful pricing of a $60 million public offering on November 28, 2025, providing crucial funding to advance its lead drug candidate PAS-004 through clinical development. The clinical-stage biotechnology company priced 80 million shares of common stock at $0.75 per share, with the offering led by healthcare-dedicated investors including Vivo Capital (搜索), Janus Henderson Investors (搜索), Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management.
Novel MEK Inhibitor in Clinical Development
PAS-004 is a next-generation macrocyclic oral MEK (搜索) inhibitor specifically designed for treating neurofibromatosis type 1 (搜索)-associated plexiform neurofibromas (搜索) (NF1-PN), RASopathies (搜索), and MAPK pathway-driven tumors (搜索). The company is currently conducting two Phase 1 clinical trials: one in advanced cancer (搜索) patients (NCT06299839) and a Phase 1/1b trial in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NCT06961565).
The MEK (搜索) inhibitor represents a targeted approach to treating diseases driven by aberrant MAPK pathway (搜索) signaling, which plays a crucial role in various cancers and genetic disorders. Neurofibromatosis type 1 (搜索) is a genetic disorder that affects approximately 1 in 3,000 individuals worldwide, often leading to the development of plexiform neurofibromas (搜索) that can cause significant morbidity.
Strategic Funding and Extended Runway
The gross proceeds of approximately $60 million, before deducting placement agent fees and other offering expenses, will extend Pasithea's cash runway through at least the first half of 2028. H.C. Wainwright & Co. (搜索) served as the exclusive placement agent for the offering, which is expected to close on or about December 1, 2025.
The company plans to use the net proceeds for general corporate purposes, including ongoing research and pre-clinical studies, clinical trials, development of new biological and pharmaceutical technologies, and potential strategic investments or acquisitions. The funding will also support licensing activities related to current and future product candidates and working capital needs.
Clinical Trial Progress and Development Strategy
Pasithea's dual-track clinical approach demonstrates the versatility of PAS-004 across different patient populations. The Phase 1 trial in advanced cancer (搜索) patients aims to establish safety, tolerability, pharmacokinetic, and pharmacodynamic profiles while exploring preliminary efficacy signals. Simultaneously, the Phase 1/1b trial in NF1 patients specifically targets the plexiform neurofibroma indication, addressing a significant unmet medical need in this rare disease population.
The company's focus on RASopathies (搜索) and MAPK pathway (搜索)-driven diseases positions PAS-004 to potentially address multiple therapeutic areas where current treatment options remain limited. The macrocyclic design of the MEK (搜索) inhibitor may offer advantages in terms of selectivity, potency, and potentially reduced side effects compared to existing MEK inhibitors.
Market Position and Future Outlook
The successful completion of this funding round reflects investor confidence in Pasithea's clinical development strategy and the therapeutic potential of PAS-004. The participation of established healthcare investors suggests strong institutional support for the company's approach to targeting the MEK (搜索) pathway in rare diseases and oncology.
With the extended cash runway through 2028, Pasithea is positioned to advance PAS-004 through multiple clinical milestones and potentially expand its development program. The company's forward-looking statements acknowledge the inherent risks in clinical development, including the possibility that future trial results may not match observed data or may not reach statistical significance required for regulatory approval.